#ASCO18 Educational Booklet Published

We are delighted to bring you the #BOPA Bursary Scheme Post ASCO 2018 Educational Booklet produced by the BOPA Bursary team.  See http://www.bopawebsite.org/bursary/documents

In this interactive document we have included our thoughts on the latest scientific data in oncology from ASCO18.  We present detailed discussion of our views of the trials the BOPA bursary team’s top ten highlights and hidden gems from ASCO. 

The report is interactive with embedded QR codes that link to accompanying videos and websites, you will need a QR code reader on your phone to scan the codes whch should work when you view it on screen.  We hope you like it.

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article